Financial News Search | Sharemaestro Newsreel

14:45 27 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex Pharmaceuticals (VRTX) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended June 2026, with an expected EPS of $4.85 and revenues of $3.23 billion. Despite the positive growth outlook, the Zacks Earnings ESP is negative (-0.86%), suggesting …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

11:31 27 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Vertex Pharmaceuticals (VRTX) Projected to Announce Quarterly Earnings on Monday

Vertex Pharmaceuticals (VRTX) is anticipated to announce its Q2 2026 earnings after the market closes on Monday, August 3rd, with analysts forecasting earnings of $4.74 per share and revenue of $3.2285 billion. The company reported strong Q1 2026 results, beating consensus estimates, and analysts …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

11:01 27 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Lombard Odier Asset Management Switzerland SA Cuts Position in Vertex Pharmaceuticals Incorporated $VRTX

Lombard Odier Asset Management Switzerland SA significantly reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 20.4% in the first quarter, selling 2,380 shares and retaining 9,312 shares valued at $4.16 million. Despite this, institutional investors collectively own 90.96% of VRTX. Vertex Pharmaceuticals reported strong …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

11:01 27 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

OMERS ADMINISTRATION Corp Has $8.39 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

OMERS ADMINISTRATION Corp increased its stake in Vertex Pharmaceuticals (VRTX) by 21.4% in the first quarter, holding 18,797 shares valued at $8.39 million. Vertex Pharmaceuticals exceeded Q1 earnings expectations and maintains a "Moderate Buy" consensus from analysts with an average price target of $559.61. …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

08:10 27 Jul 2026

TradingKey Market update Main company 🇺🇸 United States

BDRX|Biodexa Pharmaceuticals PLC|Price:1.650|Chg%:-0.030

This article provides a real-time stock quote and detailed financial analysis for Biodexa Pharmaceuticals PLC (BDRX). It includes key figures, market trends, analyst ratings, and technical indicators, along with a company overview and major shareholders. The stock is currently trading at $1.58, down 4.24% …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

19:11 26 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

AMPH|Amphastar Pharmaceuticals Inc|Price:19.180|Chg%:+0.460

This article provides a comprehensive stock analysis of Amphastar Pharmaceuticals Inc (AMPH) by TradingKey. It highlights the company's relatively healthy fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. While institutional ownership is very high and analysts generally rate it as a …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

19:11 26 Jul 2026

Simply Wall Street Market update Main company 🇺🇸 United States

Agios Pharmaceuticals (AGIO) Could Be 11% Undervalued Following Mixed Sickle Cell Updates

Agios Pharmaceuticals (AGIO) shares are reacting to mixed sickle cell disease updates, leading to an 8.21% drop in the last 7 days, despite a 48.83% gain over 90 days. The company ended development of tebapivat for sickle cell but secured FDA Priority Review for …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

11:09 26 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Sei Investments Co. Sells 230,797 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Sei Investments Co. significantly reduced its stake in Vertex Pharmaceuticals (VRTX) by 63.4% in the first quarter, selling 230,797 shares. Despite this, other institutional investors have slightly increased their positions in the pharmaceutical company. Analyst ratings for Vertex Pharmaceuticals generally remain positive, with a …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

11:09 26 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Healthcare of Ontario Pension Plan Trust Fund Purchases 20,523 Shares of Vertex Pharmaceuticals Incorporated $VRTX

The Healthcare of Ontario Pension Plan Trust Fund increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 23.4% in the first quarter, purchasing an additional 20,523 shares and bringing its total holdings to 108,251 shares valued at approximately $48.3 million. This strategic investment follows Vertex's …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

09:09 26 Jul 2026

TradingKey Market update Main company 🇺🇸 United States

Vertex Pharmaceuticals Inc (VRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Vertex Pharmaceuticals Inc (VRTX) regarding its dividends and stock splits. It notes that the company has not distributed any dividends over the past five years. The page displays key financial data for VRTX, including its stock price, market cap, …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

21:14 25 Jul 2026

https://hrtoday.in/ Market update Main company 🇺🇸 United States

Hemant Patel Joins Vertex Pharmaceuticals as Vice President, Total Rewards, Organization Development & Culture

Hemant Patel has been appointed as Vice President, Total Rewards, Organization Development & Culture at Vertex Pharmaceuticals. In this role, he will lead global initiatives in total rewards, organizational development, culture, talent, learning, and workforce strategy. Patel brings over 20 years of experience from …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

10:40 25 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

FENC|Fennec Pharmaceuticals Inc|Price:9.990|

Fennec Pharmaceuticals Inc. (FENC) shows strong fundamentals and growth potential, despite recent weak stock market performance. The company's product, PEDMARK, an approved therapy for cisplatin-induced ototoxicity in pediatric cancer patients, drives its high revenue growth. Analysts have issued "Buy" ratings with a target price …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

06:36 25 Jul 2026

AD HOC NEWS Earnings Main company 🇺🇸 United States

Vertex Pharma stock trades near record levels as cystic fibrosis franchise drives earnings growth

Vertex Pharmaceuticals (US92532F1003) stock is trading near record levels, driven by strong earnings and cash generation from its cystic fibrosis (CF) franchise, notably TRIKAFTA. The company reported double-digit revenue growth in 2023, reaching $9.9 billion, and continued this trend in Q1 2024, supported by …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

23:39 24 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

GLMD|Galmed Pharmaceuticals Ltd|Price:0.513|Chg%:-0.040

This article provides a detailed overview of Galmed Pharmaceuticals Ltd (GLMD), covering its current market trends, financial performance, and analyst ratings. It highlights the company's focus on developing therapeutics for liver diseases, particularly its flagship product Aramchol for NASH. Despite recent weak stock market …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

22:00 24 Jul 2026

finance.yahoo.com Market update Main company 🇲🇽 Mexico

Vortex Energy Corp. Announces Marketing Program

VORTEX ENERGY CORP VANCOUVER, British Columbia, July 24, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) ("Vortex" or the "Company") announces that it has engaged MCS Market Communication Service GmbH ("MCS") (address: Rheinpromenade 13, 0789 Monheim am Rhein; email: …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +16.9%

20:09 24 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

AVIR|Atea Pharmaceuticals Inc|Price:4.730|Chg%:-0.020

Atea Pharmaceuticals Inc. (AVIR) closed at $4.73, down 0.42%, with a market cap of $378.53 million. TradingKey analysis indicates stable fundamentals, high growth potential, and a "fairly valued" status within the Biotechnology & Medical Research industry, despite a short-term trend expected to move downwards. …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

17:11 24 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

SXTP|60 Degrees Pharmaceuticals Inc|Price:1.480|Chg%:-0.010

This article provides a comprehensive stock analysis of 60 Degrees Pharmaceuticals Inc (SXTP), highlighting its healthy fundamentals, significant growth potential, and "fairly valued" status. The company specializes in developing medicines for infectious diseases, with a strong revenue and profit growth. Despite recent stock market …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

13:17 24 Jul 2026

Investing.com Canada Market update Main company 🇺🇸 United States

Form 4 Vertex Pharmaceuticals Inc For: 24 July By Investing.com

This article announces the filing of Form 4 by Vertex Pharmaceuticals Inc. on July 24. Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of the company's stock. The article is brief and primarily serves …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

12:41 24 Jul 2026

TradingKey Analyst action Main company 🇺🇸 United States

JAZZ|Jazz Pharmaceuticals PLC|Price:254.835|Chg%:+0.965

This article provides a comprehensive stock analysis of Jazz Pharmaceuticals PLC (JAZZ) by TradingKey, highlighting its healthy fundamentals, high growth potential, and current "Buy" rating from analysts with a target price of $269.204. Despite a strong stock market performance, technical indicators suggest a sideways …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

21:13 23 Jul 2026

Stock Titan Earnings Main company 🇲🇽 Mexico

Vertex Pharmaceuticals (VRTX) EVP Amit Sachdev receives 8,251-share equity grant

Vertex Pharmaceuticals' EVP Amit Sachdev was granted 8,251 shares of common stock as a restricted stock unit award on July 21, 2026, which vests on March 31, 2030. This award, valued at $0.00 per share, increases his direct holdings to 66,512 shares, alongside indirect …

VRTX main company VRTX main company

Sharemaestro market context Trend signal active 52 weeks +16.9%

00:08 23 Jul 2026

Market source Earnings Main company 🇲🇽 Mexico

Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Vertex Pharmaceuticals (VRTX) recently closed with a -1.96% dip, underperforming the broader S&P 500 and Nasdaq. Despite this, the stock has gained 2.9% over the past month and analysts project optimistic earnings and revenue growth for its upcoming August 3, 2026, earnings release. The …

VRTX main company VRTX main company VRTX main company

Sharemaestro market context Trend signal active 52 weeks +16.9%

21:53 22 Jul 2026

BioPharma Dive Deals and strategy Main company 🇺🇸 United States

Vertex was sole bidder in high-premium Crinetics acquisition

Vertex Pharmaceuticals was the sole bidder in its planned $10 billion acquisition of Crinetics Pharmaceuticals, a deal valued at an unusually high 102% premium. This lack of other serious contenders and the high price tag are raising concerns among some investors who believe Vertex …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

09:12 22 Jul 2026

Stock Titan Deals and strategy Main company 🇺🇸 United States

Crinetics Pharmaceuticals (NASDAQ: CRNX) backs $85-per-share cash sale to Vertex

Crinetics Pharmaceuticals' Board of Directors has unanimously approved an $85-per-share all-cash acquisition by Vertex Pharmaceuticals. The deal, which values Crinetics at an attractive premium, follows extensive negotiations and a review of strategic alternatives. Shareholders will vote on the merger, which is expected to close …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

09:11 22 Jul 2026

MLex Deals and strategy Main company 🇺🇸 United States

Vertex-Crinetics Pharmaceuticals deal faces Australian review

Australia's antitrust watchdog, the Australian Competition & Consumer Commission (ACCC), is reviewing Vertex Pharmaceuticals' proposed acquisition of Crinetics Pharmaceuticals. The ACCC is concerned about the deal's potential impact on competition, given Vertex's existing product offerings in Australia and Crinetics' single product, Palsonify, which is …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

05:11 22 Jul 2026

Quartr Market update Main company 🇺🇸 United States

Crinetics Pharmaceuticals (CRNX) Piper Sandler 36th Annual Healthcare Conference summary

Crinetics Pharmaceuticals presented at the Piper Sandler 36th Annual Healthcare Conference, highlighting advancements in their drug pipeline. Key updates include plans for an IND submission in 2025 for a Graves' disease and thyroid eye disease program, and an IND expected in early 2025 for …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

10:39 21 Jul 2026

marketscreener.com Analyst action Main company 🇺🇸 United States

Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19

Morgan Stanley has downgraded Vertex Pharmaceuticals (VRTX) from "Overweight" to "Equalweight" and significantly reduced its price target from $19 to $15. This adjustment reflects a more cautious outlook from the investment bank regarding the pharmaceutical company's future performance. The article also notes other recent …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

02:09 21 Jul 2026

Simply Wall Street Deals and strategy Main company 🇺🇸 United States

Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal Plans

Vertex Pharmaceuticals (VRTX) stock is currently trading below its estimated intrinsic value, according to a Discounted Cash Flow (DCF) model, despite a mixed picture from broader valuation checks and an upcoming $10 billion acquisition of Crinetics Pharmaceuticals. While the DCF analysis suggests a 32.5% …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

23:00 20 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.06% at $480.50. This change lagged the S&P 500's daily loss of 0.19%. Elsewhere, the Dow lost 0.59%, while the tech-heavy Nasdaq lost 0.05%. Shares of the drugmaker have appreciated by 7.53% over the …

VRTX main company VRTX main company

Sharemaestro market context Trend signal active 52 weeks +16.9%

17:37 20 Jul 2026

MarketWatch Market update Main company 🇺🇸 United States

Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors

Shares of Vertex Pharmaceuticals Inc. (VRTX) fell 1.06% on Monday, closing at $480.50. This underperformance occurred during a generally poor trading session where the S&P 500 Index declined by 0.19% and the Dow Jones Industrial Average dropped by 0.59%. This marks the second consecutive …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

15:14 20 Jul 2026

ad-hoc-news.de Earnings Main company 🇺🇸 United States

Vertex Pharma stock trades near highs as cystic fibrosis portfolio drives double digit revenue growt

Vertex Pharmaceuticals (Vertex Pharma) stock is trading near highs due to robust revenue and profit growth driven by its cystic fibrosis (CF) portfolio. The company reported double-digit revenue increases and strong operating margins in its latest quarter, primarily from its CF treatments. Vertex is …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

13:03 20 Jul 2026

www.marketscreener.com Analyst action Main company 🇺🇸 United States

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating

Goldman Sachs has increased its price target for Vertex Pharmaceuticals to $652 from $641. The firm has concurrently maintained a "Buy" rating on the stock. This adjustment reflects Goldman Sachs' continued positive outlook on Vertex Pharmaceuticals.

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

12:31 20 Jul 2026

BioSpace Earnings Main company 🇺🇸 United States

Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals

Vertex Pharmaceuticals' IgA nephropathy drug, povetacicept, is gaining momentum following recent FDA approvals for competing therapies from Novartis (Fabhalta) and Vera Therapeutics (Trutakna). Analysts believe these approvals will help educate the market and create a positive environment for povetacicept, despite Vertex's later entry. The …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

10:41 20 Jul 2026

Quartr Deals and strategy Main company 🇺🇸 United States

Crinetics Pharmaceuticals (CRNX) Proxy filing Summary

Vertex Pharmaceuticals is set to acquire Crinetics Pharmaceuticals for approximately $10 billion ($8.8 billion net of cash), paying $85 per share in cash. This acquisition will bring PALSONIFY and atumelnant into Vertex's portfolio, with an expected combined peak annual revenue potential of over $5 …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

10:09 20 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

How FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story

Earlier this month, the FDA expanded approval of Vertex Pharmaceuticals' gene therapy Casgevy (exagamglogene autotemcel) to children aged 2 and older with sickle cell disease and transfusion-dependent thalassemia, following strong efficacy signals in two small pediatric trials. This milestone meaningfully widens access to a …

VRTX main company VRTX main company VRTX main company

Sharemaestro market context Trend signal active 52 weeks +16.9%

06:07 20 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals' gene therapy exagamglogene autotemcel (Casgevy) has received expanded FDA approval. The approval now includes children as young as 2 years old with …

VRTX main company VRTX main company

Sharemaestro market context Trend signal active 52 weeks +16.9%

23:08 19 Jul 2026

The Globe and Mail Deals and strategy Main company 🇺🇸 United States

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching

Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion to diversify its portfolio beyond its dominant cystic fibrosis drug market. The acquisition introduces Palsonify for acromegaly and pipeline candidates like atumelnant for congenital adrenal hyperplasia, anticipated to add $5 billion in peak annual sales. …

VRTX main company

Sharemaestro market context Trend signal active 52 weeks +28.0%

157 matching headlines